Edwards Lifesciences Corp.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Edwards Lifesciences Corp.
An FDA advisory panel will discuss Abbott’s PMA for the TriClip G4 transcatheter tricuspid valve repair device on 13 February. The group’s discussion will likely focus on the lack of a clear mortality or hospitalization benefit in the TRILUMINATE pivotal trial.
Edwards' Evoque is the first transcatheter therapy to receive FDA approval for the treatment of tricuspid regurgitation. The FDA-approved labeling says it can improve patients' "health status" but the company may be able to soon upgrade that indication to include a mortality benefit claim, which could give Evoque an important advantage over tricuspid valve repair devices.
Medtech Insight's News We're Watching highlights medtech industry developments we are following: Intuitive announced an FDA filing for its da Vinci 5 surgical robot; Roche hits at CGM plans; Abbott launches a new smaller rechargeable deep brain stimulator; CroiValve starts transcatheter tricuspid valve trial; ReWalk rebrands as Lifeward; and more news you may have missed.
JPM 2024 Roundup: Abbott And Medtronic Push Diabetes Tech, Edwards Updates Tricuspid Progress, Shockwave Bets On R&D
Medtech Insight covered the major announcements from medtech companies during the J.P. Morgan Healthcare Conference in early January. Here are a few more highlights from companies that may not have made the headlines but will, no doubt, make noise in 2024.
- Implantable Devices
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- CardiAQ Valve Technologies, Inc.
- CAS Medical Systems, Inc.
- Embrella Cardiovascular, Inc.
- Harpoon Medical, Inc.
- Percutaneous Valve Technologies, Inc.
- Valtech Cardio, Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.